The Effect of Bupivacaine in The Prevention of Postoperative Pain Curettage

Clinical Trial Comparing The Effects Of Injection And Non-injection Transcervical Intrauterine Bupivacaine For The Management Of Postoperative Pain Following Uterine Curettage Under General Anesthesia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015010616119N3

Enrollment

Registered

2015-01-30

Start date

2014-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain. Analgesics, antipyretics and anti-inflammatory drugs

Interventions

Intervention 1: Group I: Transcervical intrauterine injection of 15 ml of bupivacaine (0.125 %) using a urinary catheter after anesthesia. Intervention 2: Group II: Patients does not receive bupivacai

Prevention

Group I: Transcervical intrauterine injection of 15 ml of bupivacaine (0.125 %) using a urinary catheter after anesthesia.

Group II: Patients does not receive bupivacaine (Control group) .

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Woman undergoing curettage surgery. Exclusion Criteria: History of heart disease; Convulsion; Sensitivity to local anesthetic.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 1, 2, 3, 4, 8 and 12 hours after injection of bupivacaine. Method of measurement: visual analog scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Akhondzadeh

Imam Khomeini Hospital

rezaakh@hotmail.com+98 61 3221 6504

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026